Payment overview · 2025
General Payments
$768.76
18 reported records · 13 companies
Healthcare provider profile · identity verified
Tommy Curtis, NP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · CHATSWORTH, GA · NPI 1134546831
Verified facts
What the public records show
CMS Open Payments records show Tommy Curtis, NP received $768.76 in general payments during 2025 across 18 reported records.
Amgen Inc. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $124.99 | 16.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.87 | 16.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $118.80 | 15.4% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $104.62 | 13.6% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $100.05 | 13.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.39 | 5.5% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.28 | 5.4% | 2 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $25.99 | 3.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $20.36 | 2.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.23 | 2.4% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.67 | 2.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.48 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.03 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $768.76 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $124.99 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $124.87 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $118.80 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $104.62 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $100.05 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $41.28 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $41.28 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $41.28 | 2 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $25.99 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $22.70 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $19.69 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.23 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.48 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
31 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 266 | 242 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 216 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 160 | 84 |
| Atorvastatin Calcium | Atorvastatin Calcium | 153 | 84 |
| Lisinopril | Lisinopril | 134 | 76 |
| Amlodipine Besylate | Amlodipine Besylate | 127 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 123 | 69 |
| Cefdinir | Cefdinir | 109 | 104 |
| Gabapentin | Gabapentin | 92 | 50 |
| Omeprazole | Omeprazole | 91 | 55 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 86 | 80 |
| Pantoprazole Sodium | Pantoprazole Sodium | 86 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 58 |
| Doxycycline Hyclate | Doxycycline Hyclate | 73 | 70 |
| Metformin Hcl | Metformin Hcl | 73 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 41 |
| Meloxicam | Meloxicam | 67 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 62 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 31 |
| Losartan Potassium | Losartan Potassium | 59 | 37 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 54 | 52 |
| Trazodone Hcl | Trazodone Hcl | 53 | 30 |
| Furosemide | Furosemide | 48 | 35 |
| Sertraline Hcl | Sertraline Hcl | 48 | 25 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 29 |
| Montelukast Sodium | Montelukast Sodium | 44 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 36 |
| Buspirone Hcl | Buspirone Hcl | 42 | 25 |
| Famotidine | Famotidine | 41 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 41 | 23 |
| Carvedilol | Carvedilol | 40 | 23 |
| Ondansetron Odt | Ondansetron | 40 | 32 |
| Eliquis | Apixaban | 39 | 19 |
| Tramadol Hcl | Tramadol Hcl | 39 | 27 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | 19 |
| Alprazolam | Alprazolam | 37 | 18 |
| Fluconazole | Fluconazole | 37 | 32 |
| Clonazepam | Clonazepam | 35 | 16 |
| Mupirocin | Mupirocin | 35 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 34 | 19 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 22 |
| Ozempic | Semaglutide | 32 | 17 |
| Methylprednisolone | Methylprednisolone | 31 | 30 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 16 |
| Allopurinol | Allopurinol | 28 | 16 |
| Metformin Hcl Er | Metformin Hcl | 28 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | 18 |
| Glipizide | Glipizide | 27 | 19 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 27 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 26 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 25 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 24 | 22 |
| Glimepiride | Glimepiride | 22 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | 11 |
| Promethazine Hcl | Promethazine Hcl | 22 | 14 |
| Fenofibrate | Fenofibrate | 21 | 13 |
| Methocarbamol | Methocarbamol | 21 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 21 | 13 |
| Simvastatin | Simvastatin | 21 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 19 | 12 |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | 11 |
| Finasteride | Finasteride | 18 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Spironolactone | Spironolactone | 16 | 11 |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | 11 |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Cephalexin | Cephalexin | 14 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Jardiance | Empagliflozin | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | 11 |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Trulicity | Dulaglutide | 13 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $768.76 · 18 records | Amgen Inc. | ABRYSVO, ACCRUFER, AREXVY, AVVIGO Guidance System, Auvelity, BREZTRI, CAPLYTA, COMIRNATY, EVENITY, FARXIGA, GVOKE HYPOPEN, INSPIRE, MOUNJARO, NEXLETOL, PREVNAR 20, SHINGRIX, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error